No Data
No Data
Fuso Pharmaceutical Industries: Confirmation letter
Fuso Pharmaceutical Industries: Securities Report - 101st Fiscal Year (April 1, 2023 - March 31, 2024)
Fuso Pharmaceutical Industries: Extraordinary Report
Convertible Stock List (Part 2) [Parabolic Signal Convertible Stock List]
○ List of sales conversion stocks market code stock name closing price SAR Tokyo Stock Exchange Prime <1813> Fudo Tetra 2203 2357 <2211> Fujiya 2454 2490 <2269> Meiji HD 3458 3780 <2378> Renaissance 982 1015 <2389> Digital HD
Pursue high-growth companies! Fiscal Year Ending 25/3 [Increase in Sales and Profit] List <Special Feature on Growth Stocks> 5/10 Edition
As financial results announcements for the fiscal year ending March 31, '24 are in full swing, market attention is focused on the earnings forecast for the fiscal year ending 25/3, which will be announced at the same time. Demand for semiconductors is expected to recover this fiscal year, and it seems that there are many views that the upward trend in profit will continue, as domestic demand-related expansion is also expected against the backdrop of the penetration of price increases and an increase in inbound consumption due to depreciation of the yen. There is also growing interest in movements to strengthen shareholder returns aimed at improving capital efficiency. Increase for the fiscal year ending 25/3 from the financial results announced today in this special issue
Fuso Pharmaceutical Industries: Summary of financial results for the fiscal year ending 2024/3 [Japanese GAAP] (unconsolidated)
No Data